Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Shares Outstanding (2016 - 2025)

Cardiff Oncology's Shares Outstanding history spans 14 years, with the latest figure at $61000.0 for Q4 2025.

  • For Q4 2025, Shares Outstanding fell 99.91% year-over-year to $61000.0; the TTM value through Dec 2025 reached $61000.0, down 99.91%, while the annual FY2025 figure was $61000.0, 99.91% down from the prior year.
  • Shares Outstanding for Q4 2025 was $61000.0 at Cardiff Oncology, roughly flat from $61000.0 in the prior quarter.
  • Across five years, Shares Outstanding topped out at $66.5 million in Q1 2025 and bottomed at $61000.0 in Q1 2024.
  • The 5-year median for Shares Outstanding is $44.0 million (2022), against an average of $32.3 million.
  • The largest YoY upside for Shares Outstanding was 108959.02% in 2025 against a maximum downside of 99.91% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $716000.0 in 2021, then skyrocketed by 6139.8% to $44.7 million in 2022, then plummeted by 99.86% to $61000.0 in 2023, then surged by 108955.74% to $66.5 million in 2024, then tumbled by 99.91% to $61000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Shares Outstanding are $61000.0 (Q4 2025), $61000.0 (Q3 2025), and $66.5 million (Q2 2025).